Compare CAPL & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPL | GOSS |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 782.2M | 726.8M |
| IPO Year | 2012 | 2019 |
| Metric | CAPL | GOSS |
|---|---|---|
| Price | $20.82 | $3.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | 22.7K | ★ 4.0M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 10.13% | N/A |
| EPS Growth | ★ 129.06 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $3,418,591,000.00 | $44,051,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.41 |
| P/E Ratio | $17.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.61 | $0.76 |
| 52 Week High | $25.73 | $3.87 |
| Indicator | CAPL | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 51.00 |
| Support Level | $20.51 | $3.37 |
| Resistance Level | $21.23 | $3.87 |
| Average True Range (ATR) | 0.39 | 0.26 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 74.70 | 18.94 |
CrossAmerica Partners LP is engaged in the wholesale distribution of motor fuel and the ownership and leasing of real estate used in the retail distribution of motor fuel. The company operates through two business segments namely Wholesale and Retail. The Wholesale segment is a key revenue driver and includes the wholesale distribution of motor fuel to lessee dealers, independent dealers, commission agents, DMS, Circle K, and through company-operated retail sites. The Retail segment includes the sale of convenience merchandise items, the retail sale of motor fuel at company-operated retail sites, and the retail sale of motor fuel at retail sites operated by commission agents.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.